Predicting relapse risk after visceral leishmaniasis
Part of Infections, Skin clinical trials.
This study looks at a prognostic score to predict whether visceral leishmaniasis (VL) will come back after treatment. If you qualify, your information may help doctors estimate relapse risk and plan follow-up more safely.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have confirmed visceral leishmaniasis (VL), either by symptoms checked by a clinician or lab testing
- You are 12 years old or older
- You are not already on VL treatment for 3 days or more
- Your health condition is stable enough for study participation (no severe critical illness)
- You can attend required follow-up visits, or be reached by phone for follow-up updates
- You are not pregnant and not breastfeeding
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at better ways to treat visceral leishmaniasis (a serious parasitic infection) when it comes back in people who also have HIV. It may help find a plan that works longer and reduces the chance of relapse.
This study looks at people diagnosed with visceral leishmaniasis, a serious infection caused by a parasite. It aims to learn more about the condition and how it affects people in the Emilia-Romagna region.
This study tests how your immune system responds to parts of a potential vaccine for leishmaniasis. Doctors will take small blood or skin samples to see if your body's cells react to these vaccine pieces, which could help design a better vaccine in the future.
This study watches how leishmaniasis affects children over time. It helps doctors learn more about the disease in kids so they can improve care.
This study looks at how the immune system reacts to Leishmania infection and searches for new ways to diagnose the disease. It may help develop better tests for leishmaniasis.
This study tests two new oral medicines compared to an existing oral medicine for people with a first episode of cutaneous leishmaniasis (skin sores caused by a parasite). It aims to find a more effective and convenient treatment.
Hear when a new Visceral Leishmaniasis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.